Information about the impact of Xolair on pregnancy, breast-feeding and fertility.
11 __________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

- A moderate amount of data on pregnant women (between 300 and 1,000 pregnancy outcomes) based on pregnancy registry and post-marketing spontaneous reports, indicates no malformative or foeto/neonatal toxicity
-
A prospective pregnancy registry study (EXPECT) in 250 pregnant women with asthma exposed to Xolair showed the prevalence of major congenital anomalies was similar (8.1% vs 8.9%) between EXPECT and disease-matched (moderate and severe asthma) patients
- The interpretation of data may be impacted due to methodological limitations of the study, including small sample size and non-randomised design
- Care should be taken when prescribing in pregnancy as medicines can cross the placenta and may affect the foetus

- Immunoglobulins G are present in human milk and it is therefore expected that Xolair will be present in human milk. Available data in non-human primates have shown excretion of Xolair into milk
-
Data from the EXPECT study including 154 infants who had been exposed to Xolair during pregnancy and through breast-feeding did not indicate adverse effects in the breast-fed infant
- The interpretation of data may be impacted due to methodological limitations of the study, including small sample size and non-randomised design
- Given orally, immunoglobulin G proteins undergo intestinal proteolysis and have poor bioavailability. No effects on the breast-fed newborns/infants are anticipated

- There are no human fertility data for Xolair
- In specifically-designed non-clinical fertility studies in non-human primates, including mating studies, no impairment of male or female fertility was observed following repeated dosing with Xolair up to 75 mg/kg
- No genotoxic effects were observed in a separate non-clinical genotoxicity study
Indication: Xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1-antihistamine treatment.1
Reference
- Xolair® (omalizumab) 150 mg Summary of Product Characteristics.